Preprint Review Version 1 This version is not peer-reviewed

Metabolic Syndrome: Current State and Prospects

Version 1 : Received: 28 October 2024 / Approved: 28 October 2024 / Online: 29 October 2024 (08:49:22 CET)

How to cite: Zhang, W.-Z. Metabolic Syndrome: Current State and Prospects. Preprints 2024, 2024102224. https://doi.org/10.20944/preprints202410.2224.v1 Zhang, W.-Z. Metabolic Syndrome: Current State and Prospects. Preprints 2024, 2024102224. https://doi.org/10.20944/preprints202410.2224.v1

Abstract

Metabolic syndrome (MetS), first conceptualized in 1923, encompasses a cluster of metabolic abnormalities, including insulin resistance (IR), hyperglycemia, dyslipidemia, hypertension, and central obesity. This syndrome significantly increases the risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Its global prevalence has surged, largely attributed to lifestyle factors such as poor diet and physical inactivity. Recent research highlights the crucial role of caveolae, small cellular structures, in the pathophysiology of MetS, particularly in insulin signaling, lipid metabolism, and vascular function. Managing MetS effectively requires a comprehensive strategy focused on lifestyle modifications and pharmacological treatments. Dietary approaches, environmental factors, regular physical activity and behavioral changes have demonstrated positive impacts on metabolic health. Despite current pharmacological options to individual conditions of MetS, emerging therapies targeting caveolae offer promising new avenues for treatment. While, microbiome modulation and certain natural agents may assist in managing the syndrome. Public health initiatives, including educational campaigns and stress reduction programs, are essential for the prevention and management of MetS. A multifaceted approach combining lifestyle changes, pharmacotherapy, and personalized interventions is vital for effective management. Future strategies may benefit from precision medicine and the integration of emerging biomarkers for targeted therapies.

Keywords

 Caveolae; Metabolic diseases; Lifestyle alteration; Personalized medicine  

Subject

Medicine and Pharmacology, Endocrinology and Metabolism

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.